Clinical Trials
3 trialsNCT03291288 2021-05-14
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Daiichi Sankyo
Phase 1 Completed
NCT01185548 2018-10-19
JZAR
Eli Lilly and Company
Phase 1 Terminated
NCT01218620 2014-12-23
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed